Unknown

Dataset Information

0

AAV9-mediated central nervous system-targeted gene delivery via cisterna magna route in mice.


ABSTRACT: Current barriers to the use of adeno-associated virus serotype 9 (AAV9) in clinical trials for treating neurological disorders are its high expression in many off-target tissues such as liver and heart, and lack of cell specificity within the central nervous system (CNS) when using ubiquitous promoters such as human cytomegalovirus (CMV) or chicken-?-actin hybrid (CAG). To enhance targeting the transgene expression in CNS cells, self-complementary (sc) AAV9 vectors, scAAV9-GFP vectors carrying neuronal Hb9 and synapsin 1, and nonspecific CMV and CAG promoters were constructed. We demonstrate that synapsin 1 and Hb9 promoters exclusively targeted neurons in vitro, although their strengths were up to 10-fold lower than that of CMV. In vivo analyses of mouse tissue after scAAV9-GFP vector delivery via the cisterna magna revealed a significant advantage of synapsin 1 promoter over both Hb9 variants in targeting neurons throughout the brain, since Hb9 promoters were driving gene expression mainly within the motor-related areas of the brain stem. In summary, this study demonstrates that cisterna magna administration is a safe alternative to intracranial or intracerebroventricular vector delivery route using scAAV9, and introduces a novel utility of the Hb9 promoter for the targeted gene expression for both in vivo and in vitro applications.

SUBMITTER: Lukashchuk V 

PROVIDER: S-EPMC4756767 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature

altmetric image

Publications

AAV9-mediated central nervous system-targeted gene delivery via cisterna magna route in mice.

Lukashchuk Vera V   Lewis Katherine E KE   Coldicott Ian I   Grierson Andrew J AJ   Azzouz Mimoun M  

Molecular therapy. Methods & clinical development 20160217


Current barriers to the use of adeno-associated virus serotype 9 (AAV9) in clinical trials for treating neurological disorders are its high expression in many off-target tissues such as liver and heart, and lack of cell specificity within the central nervous system (CNS) when using ubiquitous promoters such as human cytomegalovirus (CMV) or chicken-β-actin hybrid (CAG). To enhance targeting the transgene expression in CNS cells, self-complementary (sc) AAV9 vectors, scAAV9-GFP vectors carrying n  ...[more]

Similar Datasets

| S-EPMC4448732 | biostudies-literature
| S-EPMC9203269 | biostudies-literature
| S-EPMC4015314 | biostudies-literature
| S-EPMC7076453 | biostudies-literature
| S-EPMC8905628 | biostudies-literature
| S-EPMC8787364 | biostudies-literature
| S-EPMC7002897 | biostudies-literature
| S-EPMC7997047 | biostudies-literature
| S-EPMC8311521 | biostudies-literature
| S-EPMC4292043 | biostudies-literature